Innophore

You can watch the presentation here: register.nvidia.com/flow/nvidia/gt…

And we are live! Watch our CEO, Christian C. Gruber, as he presents at the NVIDIA #GTC24. We’ve gathered in our office here in Graz to join the event online.

Discover AI's impact on drug discovery with GPU-powered BioNeMo at #GTC24. On Mar 20, at 10am CET, learn how NVIDIA and @innophore innovate protein design, analyze biomolecular data, and apply insights through case studies in therapeutic breakthroughs. nvda.ws/4cebHfL

His talk with David Ruau (Head of Strategic Alliances, Drug Discovery AI, NVIDIA), focuses on "Leveraging #AI for Enzyme and Drug Discovery." Join in to hear how Innophore’s technology can be utilized for #drugdiscovery and predicting side effects using our CavitOmiX platform.

Our CEO, Christian Gruber, will be presenting at @NVIDIAGTC 2024 on Wednesday, March 20th from 10:00 AM to 10:50 AM CET (2:00 AM to 2:50 AM PDT). nvidia.com/gtc/session-ca… #GTC2024

Our COO, Bettina Nestl, will attend Bio-Europe Spring 2024 in Barcelona next week. Excited to connect and share insights on enzyme discovery, drug repurposing, and side-effect prediction! #BioEurope2024 #biotech #Biopharma #Innophore

Inspiring talks by A. Pritzel from @DeepMind and B. Nestl from @innophore about the potencial of AI in Biocatalysis #Biotrans2023 @HetBiocat

You can watch the recorded GTC 2023 livestream here: lnkd.in/dj6MANX3

NVIDIA’s CEO Jensen Huang gave his keynote at @NVIDIAGTC 2023 conference, unveiling the latest advancements in generative AI, large language models, cloud computing, and more. We could not be more proud to be among the selected #NVIDIA #BioNeMo partners 🎉

Behind the paper at @NaturePortfolio on designing variant-specific therapeutic SARS-CoV-2 decoys. The workflow features our #Catalophore™ Halos, deep #neuralnetworks and MD #simulations plus experimental validation. Read the full post here: go.nature.com/3QO7SUk

This workflow combines our #Catalophore™ Halos with deep neural networks in conjunction with MD #simulations, validated in vitro and BSL3 neutralization assays. Reducing time-to-market for #biologics is critical, fast and efficient #leadoptimization is key for many future drugs.

The year is off to an exciting start: Together with our partners @SignalChem, @awscloud, @acibGmbH, @MedUniGraz and @UniGraz we demonstrated the #AI pipeline to optimize variant-specific therapeutic SARS-CoV-2 ACE2 #decoys. nature.com/articles/s4159…

#Antiviral drugs are one of the first lines of defense in fighting viral diseases. But is there a link between antiviral drugs and the evolution of the virus? Let's find out and read our recent publication here ⬇️ frontiersin.org/articles/10.33… #SARSCoV2 #mutations

The innophore teams CavitOmiX for your #PyMol cavities #StructuralBiology @structbio@a.gup.pe #proteinstructureandfunction #enzymeengineering pymolwiki.org/index.php/Cavi…

Scientific publications often just report the hard facts, leaving out the story on what lead to the final findings. Take a look behind the scenes of one of our most recent publications and learn more about its creation in our blog post at @NaturePortfolio. go.nature.com/3NebrBk

Grazer und Wiener Wissenschafter entwickeln eine Technologie, mit der sie die Mutation von Viren beobachten und voraussagen wollen. dlvr.it/SYJPwb

Grazer ForscherInnen entwickeln Technologie zur präzisen Einschätzung der Gefährlichkeit von Virus-Varianten 🔗 news.uni-graz.at/de/detail/arti… #weworkfortomorrow 📷 @innophore, @luminous_lab #acib

Using a structural bioinformatics approach, researchers from @innophore, @UniGraz and @awscloud predict that Omicron spike receptor binding domain has a higher affinity to human ACE2 receptors, when compared to the wild type reference. nature.com/articles/s4159…

Out latest publication in @SciReports is online! We are excited to share the details on how we use our Catalophore Halo technology to rapidly track changes in the RBD/hACE2 interface. Enjoy the short video summary and visit rdcu.be/cUn8E to read the full text. #COVID19

Recent changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs. #covid researchsquare.com/article/rs-185…